Clinical ReviewAcute Bacterial Skin and Skin Structure Infections (ABSSSI): Practice Guidelines for Management and Care Transitions in the Emergency Department and Hospital
Introduction
Acute bacterial skin and skin structure infections (ABSSSI) have become a challenging medical problem associated with high direct and indirect costs to both the medical system and society. Infections due to bacteria with resistance to previously effective antimicrobials such as methicillin-resistant Staphylococcus aureus (MRSA) are increasing in incidence and have led to higher rates of complications and hospitalization. MRSA has emerged as the most common cause of purulent infections in the United States and many other areas. Meeting the challenge to deliver efficient health care not only demands that we recognize and treat individual patients; we must also define strategies to optimize patient flow and resource utilization. An important goal is to limit inpatient stays and reduce hospital readmissions through seamless transitions of care from the emergency department (ED) into the hospital medicine service, and then out to the community. The purpose of this report is to describe a best practice model for patient care and resource management in ABSSSI.
The terms “skin and skin structure infection” and “skin and soft tissue infection” (SSTI) were coined to describe infectious processes such as cellulitis, erysipelas, cutaneous abscesses, and infected wounds, ulcers, or burns. The designation of more severe SSTI included a lowercase “c” (cSSTI) for “complicated” skin and soft tissue infection and typically implied a need for inpatient management, surgical procedures, or a significant underlying comorbidity such as diabetes or systemic immunosuppression that complicates response to therapy.
In 2013, to identify more clearly a severe subset of SSTI that would typically be treated with parenteral antibiotic therapy, the United States (US) Food and Drug Administration (FDA) issued guidance that standardized the nomenclature to be used in the evaluation of new antimicrobial treatments for cSSTI, which are now referred to as acute bacterial skin and skin structure infections, or ABSSSIs. The rationale for developing this terminology was to provide a consistent means of identifying infections for which a reliable drug treatment effect can be estimated. The agents to be studied under the new definition are most often administered parenterally, and patient level of illness is reflected in parameters such as lesion size, leukocytosis, fever, and systemic inflammatory response syndrome (1).
The specific verbiage from the FDA is as follows:
ABSSSIs include cellulitis/erysipelas, wound infection, and major cutaneous abscess with a minimum lesion surface area of 75 cm2. Diabetic foot ulcers and burn wound infections are excluded. Bacterial pathogens that commonly cause ABSSSI include Streptococcus pyogenes and Staphylococcus aureus, including MRSA strains. Less commonly identified bacteria include other Streptococcus species, Enterococcus faecalis, and Gram-negative bacteria (1).
Although various terms appear in the literature and some of the studies discussed in this review used the terms cSSSI or cSSTI, we will use ABSSSI consistently to describe these complicated infections, to avoid confusion. The primary etiologic organism of concern in ABSSSI is MRSA, and most novel antimicrobials studied to date under the new FDA guidance target MRSA specifically.
Section snippets
Management of ABSSSI: Time for a New Focus
Skin and skin structure infections are common causes for presentation to the ED. The majority of these patients can be treated effectively as outpatients with oral antimicrobial agents, with or without minor surgical intervention. For patients with the more serious ABSSSI, who are deemed to require parenteral therapy, effective communication and care transition between the ED and the hospital medicine service are particularly important. A clearly defined methodology for evaluating the need for
Conclusions
Infectious agents such as MRSA are increasing in incidence and have led to higher rates of complications and hospitalization for ABSSSI. According to the National Hospital Ambulatory Medical Care Survey, the number of ED visits for skin infections almost tripled from the late 1990s until 2005, and continues to increase at an alarming rate. MRSA is prevalent in ABSSSI with high rates of morbidity and other associated medical conditions.
Patients who develop CA-MRSA are at significantly greater
Acknowledgment
Durata Therapeutics, Inc., provided an unrestricted grant to support the author group's working meetings. The Sponsor had no editorial input or right of approval/disapproval of this manuscript.
References (44)
- et al.
Recurrent bacteraemia: a 10-year regional population-based study of clinical and microbiological risk factors
J Infect
(2010) - et al.
Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004)
Diagn Microbiol Infect Dis
(2007) - et al.
Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus
Ann Emerg Med
(2008) - et al.
The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)
Clin Microbiol Infect
(2013) - et al.
Risk stratification and outcome of cellulitis admitted to hospital
J Infect
(2010) - et al.
Necrotizing fasciitis: contribution and limitations of diagnostic imaging
Joint Bone Spine
(2013) - FDA Guideline ABSSSI 2013. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071185.pdf. Accessed...
- et al.
Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship
Clin Infect Dis
(2010) - et al.
Methicillin-resistant S. aureus infections among patients in the emergency department
N Engl J Med
(2006) - et al.
Bacteriology of skin and soft tissue infections: a comparison of infections in intravenous drug users and individuals with no history of drug use
Clin Infect Dis
(1995)
Methicillin-resistant Staphylococcus aureus in community-acquired skin infections
Emerg Infect Dis
Emergency ID Net Study Group. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008
Clin Infect Dis
Antimicrobial resistance: not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician’s guide to community MRSA—its evolving antimicrobial resistance and implications for therapy
Clin Infect Dis
Microbiology of antibiotic resistance in Staphylococcus aureus
Clin Infect Dis
Comparison of community and healthcare associated methicillin resistant Staphylococcus aureus infection
JAMA
Is Panton-Valentine leukocid in the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?
J Infect Dis
Acute bacterial skin infections: developments since the 2005 Infectious Disease Society Of America (IDSA) Guidelines
J Emerg Med
Waves of resistance: Staphylococcus aureus in the antibiotic era
Nat Rev Microbiol
Methicillin-resistant Staphylococcus aureus strain USA 300: origin and epidemiology
J Antimicrob Chemother
Trends in US hospital admissions for skin and soft tissue infections
Emerg Infect Dis
National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections
Arch Intern Med
Understanding the success of methicillin-resistant Staphylococcus aureus strains causing epidemic disease in the community
J Infect Dis
Cited by (84)
Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance
2023, European Journal of Medicinal ChemistryOutpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin – A real-world data and retrospective cost analysis
2023, Journal of Infection and Public HealthSkin infections in Europe: a retrospective study of incidence, patient characteristics and practice patterns
2022, International Journal of Antimicrobial AgentsEfficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis
2021, Journal of Global Antimicrobial ResistanceCitation Excerpt :As a frequent cause of morbidity in clinical practice, acute bacterial skin and skin-structure infections (ABSSSIs) include cellulitis, major cutaneous abscess and wound infections with a minimum lesion surface area of 75 cm2, which were once referred to as complicated skin and soft-tissue infections (cSSTIs) and standardised by the US Food and Drug Administration (FDA) in 2013 [1]. Methicillin-resistant Staphylococcus aureus (MRSA), a risk factor for subsequent hospitalisation and death [2], is the most common pathogen of ABSSSIs in many countries and it has become resistant to the standard treatment agents such as vancomycin. Such infections have become a health challenge, leading to 2% of all hospitalisations and 14.2 million ambulatory visits per year in the USA [3,4].
Effectiveness of oritavancin for management of skin and soft tissue infections in the emergency department: A case series
2021, American Journal of Emergency Medicine